Severity of Respiratory Viral Diseases and the Impacts of Underlying Medical Conditions During the Omicron Subvariant Dominant Epidemics—A Comparative Study of SARS-CoV-2, Influenza Virus and Respiratory Syncytial Virus
by
, , , , , , ,
Yu Jung Choi
1,2, 
Joon Young Song
1,2,*,
Seong-Heon Wie
3,
Won Suk Choi
2,4,
Jacob Lee
5,
Jin-Soo Lee
6,
Young Keun Kim
7,
Shin Woo Kim
8,
Sun Hee Lee
9,
Kyung-Hwa Park
10,
Hye Won Jeong
11,
Jin Gu Yoon
1,2,
Hye Seong
1,2,
Eliel Nham
1,2,
Ji Yun Noh
1,2,
Hee Jin Cheong
1,2 and
Woo Joo Kim
1,2 1
Division of Infectious Diseases, Department of Internal Medicine, Guro Hospital, Korea University College of Medicine, Seoul 08308, Republic of Korea
2
Vaccine Innovation Center-KU Medicine (VIC-K), Seoul 02841, Republic of Korea
3
Division of Infectious Diseases, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon 06591, Republic of Korea
4
Division of Infectious Diseases, Department of Internal Medicine, Ansan Hospital, Korea University College of Medicine, Ansan 02841, Republic of Korea
5
Division of Infectious Diseases, Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul 05355, Republic of Korea
6
Division of Infectious Diseases, Department of Internal Medicine, Inha University School of Medicine, Incheon 22332, Republic of Korea
7
Division of Infectious Diseases, Department of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju 26426, Republic of Korea
8
Division of Infectious Diseases, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu 41404, Republic of Korea
9
Division of Infectious Diseases, Department of Internal Medicine, Pusan National University School of Medicine, Pusan 50612, Republic of Korea
10
Division of Infectious Diseases, Department of Internal Medicine, Chonnam National University Medical School, Gwangju 61469, Republic of Korea
11
Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju 28644, Republic of Korea
*
Author to whom correspondence should be addressed.
Pathogens 2025, 14(6), 543; https://doi.org/10.3390/pathogens14060543
Submission received: 4 April 2025
/
Revised: 22 May 2025
/
Accepted: 28 May 2025
/
Published: 29 May 2025
(This article belongs to the Section Viral Pathogens)
Abstract
:After the transition of coronavirus disease 2019 (COVID-19) from a pandemic to an endemic phase, data on respiratory viral infections remain limited. This study compared the clinical outcomes of SARS-CoV-2, influenza virus (INFV), and respiratory syncytial virus (RSV) infections and investigated how underlying medical conditions influence disease severity. During Omicron subvariant dominant periods, we conducted a multicenter, retrospective cohort study including laboratory-confirmed cases of SARS-CoV-2, INFV, and RSV infections in hospitalized patients aged ≥ 19 years. We compared demographic characteristics and clinical outcomes and analyzed the association between underlying comorbidities and severity of infection. A total of 1850 cases with SARS-CoV-2, 98 with INFV, and 63 with RSV infections were analyzed. Notable differences in the occurrence of fever, cough, sputum, and dyspnea were observed among patients with the three different viral infections. Pneumonia was diagnosed more frequently in patients with RSV infection (65.6%) compared to those with INFV infection (42.9%) and SARS-CoV-2 (34.4%) (p < 0.01). For patients with SARS-CoV-2 infection, the risk of pneumonia increased by 47% in the moderate-risk group and 37% in the high-risk group. Among hospitalized patients, pneumonia was more frequently identified in patients with RSV infection, with statistical significance. Furthermore, the presence of medical conditions significantly increased the risk of developing pneumonia.
1. Introduction
The coronavirus disease 2019 (COVID-19) pandemic significantly impacted the landscape of respiratory viral infections [1,2,3,4,5]. Reinforced mask use and social distancing effectively suppressed the circulation of other respiratory viruses. Notably, there was no influenza epidemic for two and a half years during the COVID-19 pandemic.
On 5 May 2023, the World Health Organization declared the end of the COVID-19 public health emergency, marking the transition to an endemic era. With the easing of social distancing measures, seasonal respiratory virus epidemics have resumed. Influenza virus (INFV), respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are circulating concurrently, leading to high morbidity and mortality. Actually, in the Republic of Korea, for instance, the seasonal influenza epidemic began earlier than usual in September 2022 [6].
Most respiratory viruses can cause lower respiratory tract infections, including bronchiolitis and pneumonia, leading to hospitalization and death. A systematic review of 31 observational studies on community-acquired pneumonia (CAP) discovered that 24.5% of cases were caused by viral infections, with approximately half (10%) being viral/bacterial co-infections [7]. Notably, older age, alcoholism, and underlying medical conditions are established risk factors for severe pneumonia requiring hospitalization [8,9,10]. Additionally, studies have revealed that the average direct medical cost for domestic hospitalized patients with CAP is more than double in the high-risk group ($2841 per person) compared to the low-risk group ($1263) [11].
SARS-CoV-2, INFV and RSV are the leading causes of respiratory viral infections in adults and frequently cause pneumonia. However, the risk factors for pneumonia and severe complications may differ among these viruses. This study aimed to compare the clinical outcomes and risk factors of severe infections among these three representative respiratory viral infections (SARS-CoV-2, INFV and RSV).
2. Materials and Methods
2.1. Study Design and Data Sources
We conducted a multicenter, retrospective cohort study involving eight hospitals located in various regions (Seoul, Suwon, Ansan, Incheon, Wonju, Daegu, Pusan, Gwangju, and Chungbuk) of the Republic of Korea, all participating in the Hospital-based Influenza Morbidity and Mortality surveillance system (HIMM). This study was conducted between 1 September 2022, and 31 August 2023, during periods when the SARS-CoV-2 Omicron subvariants circulated dominantly. We included all hospitalized patients aged 19 years or older with laboratory-confirmed SARS-CoV-2, INFV, or RSV infections during this period. Patients younger than 19 years were excluded. Respiratory virus testing was performed as part of standard clinical diagnostic procedures.
Clinical and laboratory information was obtained from the electronic medical records of each participating hospital. We analyzed and compared demographic characteristics and clinical outcomes (pneumonia, intensive care unit [ICU] admission, acute respiratory distress syndrome [ARDS], and mortality) across the three different viral groups. Additionally, we evaluated the risk of severe infection based on the presence of underlying chronic medical conditions. Vaccination status was verified through patient history (obtained through one-on-one interviews), hospital electronic records, and the Korea Disease Control and Prevention Agency’s vaccination database.
2.2. Definition
Each viral infection was defined as a case meeting the following criteria: for SARS-CoV-2 infection, a positive test result on either a SARS-CoV-2 rapid antigen test (RAT) or a SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) test; for INFV infection, a positive test result on either an INFV RAT or a respiratory virus PCR test; and for RSV infection, a positive respiratory virus PCR test. INFV and RSV were tested using multiplex PCR for respiratory viruses. We defined individuals as vaccinated if they had received the vaccine at least 14 days prior to the diagnosis.
Patients were classified into risk groups according to their underlying medical conditions. Individuals with no underlying medical conditions were assigned to the low-risk group. The moderate-risk group included those with at least one of the following medical conditions: diabetes mellitus, cardiovascular disease, cerebrovascular disease, neuromuscular disease, chronic obstructive pulmonary disease, asthma, other chronic lung diseases, chronic renal disease, or chronic liver disease. Finally, the high-risk group included patients with at least one of the following immunocompromising conditions: splenic dysfunction (including post-splenectomy), hematologic malignancy, solid cancer undergoing chemotherapy, solid organ transplantation, stem cell transplantation, human immunodeficiency virus infection, or high-dose corticosteroid use (≥20 mg/day of prednisone or equivalent for two or more weeks).
2.3. Statistical Analysis
Statistical analyses were carried out using IBM SPSS Software version 25.0 (IBM Corp., New York, NY, USA). To compare clinical features and outcomes among the three virus groups, categorical variables were assessed using the Chi-square test, while continuous variables were examined with analysis of variance (ANOVA). Categorical variables, such as the presence or absence of symptoms, were analyzed and expressed as percentages (%). Quantitative variables, such as age or duration of hospitalization, were expressed as mean ± standard deviation, rounded to one decimal place. To control for false positives, post hoc analyses were conducted following significant findings. For chi-square tests, adjusted residuals were used to identify cell-level differences, and for ANOVA, Bonferroni correction was applied. A two-tailed p-value of less than 0.05 was considered statistically significant.
To evaluate the association between underlying medical conditions and the development of clinical outcomes (pneumonia, ICU admission, and mortality), logistic regression analysis was used. This analysis estimated the odds ratio (OR) for each outcome based on the presence of specific conditions. Age, sex, and vaccination status were included as covariates in the model to account for their potential influence. Separate analyses were conducted for each underlying disease and risk group (low, moderate, and high).
2.4. Ethics Statement
This retrospective study received approval from the Institutional Review Board of each participating hospital: Korea University Guro Hospital (2022GR0360), Korea University Anam Hospital (2022AN0449), Korea University Ansan Hospital (2022AS0226), St. Vincent’s Hospital (VC22TIDI0150), Kangnam Sacred Heart Hospital (2022-07-016), Inha University Hospital (2022-07-036), Chungbuk National University Hospital (2022-08-022), and Gil Medical Center (GAIRB2022-306). This study was conducted in line with the ethical principles outlined in the Declaration of Helsinki by the World Medical Association. Given the retrospective study design, the requirement for written informed consent was waived.
3. Results
3.1. Clinical Characteristics and Outcomes of SARS-CoV-2, INFV, and RSV
A total of 2011 hospitalized patients were included in the analysis across eight medical centers from 1 September 2022, to 31 August 2023, during periods when the SARS-CoV-2 Omicron subvariants circulated dominantly: 1850 with SARS-CoV-2, 98 with INFV, and 63 with RSV infection (Table 1).
The mean age of the patients ranged from 68 to 70 years, with over 65% of patients in all three groups being older than 65 years. No significant differences in underlying medical conditions were observed among the groups, although chronic lung disease and a history of bone marrow transplantation were both more prevalent in RSV patients.
Clinical presentations varied significantly among the viral groups (Table 1). Patients with SARS-CoV-2 infection were prone to be asymptomatic and experienced less frequent cough and sputum compared to those with INFV or RSV infection. Among patients positive for each virus, those with INFV infection exhibited a higher prevalence of fever (76/98, 77.6%, p < 0.001), whereas dyspnea was more common among patients with RSV infection (40/63, 63.5%, p < 0.001; Table 1). Regarding laboratory findings, the RSV group demonstrated significantly higher erythrocyte sedimentation rates (ESR) and C-reactive protein (CRP) levels compared to the other groups. No other significant differences were observed in the laboratory findings. Chest radiography revealed pneumonia more frequently in the RSV group (65.6%) compared to the other groups (42.9% and 34.4% in the INFV and SARS-CoV-2 groups, respectively; p < 0.01). There was no difference in vaccination status between the groups.
The incidence of pneumonia differed markedly across the three viral groups: 39.8%, 24.8%, and 68.8% in patients with SARS-CoV-2, INFV, and RSV, respectively (p < 0.001; Table 2). Other clinical outcomes, such as ICU admission, ARDS, mortality, and the duration of hospitalization, did not show significant differences among the three groups. Both adjusted residuals analysis (using a significance threshold of ±1.96) and Bonferroni correction consistently confirmed the presence of significant cell-level differences across all relevant comparisons.
3.2. Impact of Underlying Medical Conditions on Disease Severity
We analyzed the risk of pneumonia development based on underlying medical conditions (Table 3).
Compared to the low-risk group, the incidence rate of SARS-CoV-2 pneumonia was significantly higher in the moderate-risk group (1.47-fold increase; 95% confidence intervals [CI]: 1.07–2.01, p = 0.017) and showed a trend toward being higher in the high-risk group (1.37-fold increase; 95% CI: 0.90–1.93, p = 0.074) (Table 3). Within the moderate-risk group, the incidence of pneumonia increased further with a rising number of chronic medical conditions (from 1.46 to 1.54 compared to the low-risk group). Details on the risk of SARS-CoV-2 pneumonia associated with specific chronic conditions are provided in Supplementary Table S1. INFV and RSV pneumonia followed a similar trend, although the increases in risk were not statistically significant.
The risk of ICU admission was also evaluated based on underlying conditions (Table 4).
For patients with SARS-CoV-2 infection, the risk of ICU admission in the moderate-risk group with three or more chronic conditions was significantly higher (a 1.38-fold increase; 95% CI: 0.96–1.99, p = 0.001) compared to the low-risk group. Notably, the risk of ICU admission in RSV patients with three or more chronic conditions was even greater (28.23-fold increase; 95% CI: 1.38–576.83, p = 0.030). Interestingly, among patients with SARS-CoV-2 infection, the ICU admission rates were the highest in the moderate-risk group, followed by the low-risk and high-risk groups, though these differences did not reach statistically significant. No significant differences were observed among risk groups among patients with INFV infection.
While not statistically significant, the mortality rate was consistently higher in the high-risk group compared to the moderate and low-risk groups for all three viral infections (Table 5). Additionally, within the moderate-risk group, there was a trend toward increasing mortality rates with a higher number of chronic medical conditions.
4. Discussion
This study evaluated the clinical outcomes of three major respiratory viruses (SARS-CoV-2, INFV, and RSV) and assessed whether underlying medical conditions influenced disease severity. The clinical presentations differed markedly; patients with SARS-CoV-2 infection exhibited a higher rate of asymptomatic infection and those with INFV infection were prone to experience fever. In comparison, patients with RSV infection had a significantly higher hospitalization rate due to dyspnea. Notably, pneumonia was significantly more prevalent among hospitalized patients with RSV infections. In patients with SARS-CoV-2 infection, the risk of pneumonia increased with the number of underlying medical conditions (1.47-fold increase in the moderate-risk group and 1.37-fold increase in the high-risk group). This trend was similar to that of the ICU admission rates. There was no significant difference in mortality rates among the three viral groups, which might be due to the high proportion (approximately 70%) of adults aged over 65 years in our study population.
Patients with RSV infections presented with severe symptoms, including dyspnea, elevated ESRs and CRP levels, and frequent pneumonia observed on chest X-rays (Table 1). However, a previous prospective study on CAP discovered that only 3.7% of adults with radiologically confirmed CAP tested positive for RSV [12]. This suggests that RSV infections might be underdiagnosed in clinical practice. Among the older population, RSV contributes to a significant disease burden, potentially equal to or exceeding that of INFV infection [13,14]. Unlike SARS-CoV-2 and INFV infections, RSV RAT is not commonly used in routine clinical practice due to the lack of effective antiviral agents. Consequently, diagnosis often relies on respiratory viral PCR testing, particularly in cases of suspected pneumonia. This may lead to an underestimation of the real disease burden and overestimation of the severity for RSV infection, highlighting the need for further well-designed prospective studies.
Several studies have investigated factors influencing the severity of respiratory virus infections [15,16,17,18,19,20,21]. Large-scale prospective studies and systematic reviews have identified old age, male sex, heart failure, and chronic kidney disease as risk factors for severe COVID-19, with age being the strongest predictor of severe illness and mortality [15,16]. Similarly, Federico et al. reported a significant increase in the burden of RSV and INFV infections among the older population [17]. As for RSV infection, Edward et al. reported a 3.97-fold increased risk of hospitalization in patients with underlying lung disease [18]. Additionally, a retrospective study conducted in China reported lower survival rates following RSV infection among elderly patients and those with congestive heart failure or chronic obstructive pulmonary disease [22]. Similarly, a study from Croatia found that chronic conditions, particularly cardiovascular and respiratory diseases, were strongly associated with higher complication rates in RSV-infected patients [23]. Consistent with these findings, our study identified old age and chronic medical conditions (both moderate and high-risk groups) as risk factors for pneumonia.
However, compared to a previous study where the risk of CAP increased by 4.32–7.57 fold in the moderate-risk group compared to the low-risk group (healthy individuals), the effect of chronic medical conditions appeared to be lower in our study [19]. This difference is potentially attributable to our study population. Unlike previous studies that included younger and outpatient populations, ours focused on hospitalized patients, most of whom were older adults. In the Republic of Korea, over 90% of individuals aged 65 years and older have at least one chronic medical condition, and more than half have three or more [24,25,26]. This high prevalence of underlying medical conditions within our study population, composed primarily of older adults, may explain the seemingly limited effect of these conditions on disease severity. For instance, our study found a 2.37-fold increased risk of pneumonia for asthma and a 1.79-fold increased risk for other chronic lung diseases (Supplementary Table S1), whereas previous studies reported a 4.16-fold increased risk in patients with chronic lung diseases. These findings suggest that the effect of underlying medical conditions on disease severity may be less pronounced in older adults.
ICU admission rates for SARS-CoV-2 were higher in the moderate-risk group and relatively lower in the high-risk group. This could be due to the larger proportion of high-risk patients with solid cancer or hematologic conditions, who might have chosen less aggressive treatments and declined ICU admission (Supplementary Table S2). Interestingly, age did not significantly influence ICU admission rates, suggesting that suggesting that older patients may have led to the avoidance of unnecessary resource allocation Similarly, ICU admission rates decreased in patients with solid cancers. However, the high-risk group exhibited a trend toward higher mortality rates, which was also observed in older patients with solid cancers (Supplementary Table S3).
This study had some limitations. First, the retrospective design may have led to an underestimation of the disease burden associated with RSV infections, as mild cases could have been missed or underreported. In particular, mild RSV infections in adults are often underestimated, underscoring the need for future research to develop and validate a standardized case definition that can facilitate more accurate diagnosis and monitoring, especially in outpatient and community settings. Large-scale, prospective studies are needed to definitively assess whether ICU admission or mortality rates are higher among patients with RSV infection compared to those with SARS-CoV-2 or INFV infections. Secondly, this study was limited to a single season shortly following the COVID-19 pandemic. The limited timeframe and relatively few INFV and RSV cases reduced the statistical power of certain comparisons. Consequently, interpretations of incidence and clinical outcomes across SARS-CoV-2, INFV, and RSV should be approached with caution, particularly given the disproportionately low number of RSV cases, which may compromise the robustness of the findings. Third, as mentioned above, most of our study population consisted of elderly hospitalized patients (69.4% aged ≥ 65 years), which may limit the generalizability of our findings to other populations. In contrast to the inconsequential impact of RSV in adults, RSV is well-known as the leading cause of bronchiolitis and pneumonia in children. Although a significant increase was observed in bronchiolitis by non-RSV pathogens (INFV A/B, metapneumovirus, adenovirus) following the COVID-19 pandemic, RSV still accounted for the largest proportion (40%) of the cases [27,28]. Finally, this study did not explore inter-viral interactions, and future research should investigate co-infections and biomarkers to better understand disease severity and prognosis.
Current RSV surveillance systems are methodologically limited, as RSV diagnosis is primarily based on PCR testing conducted on hospitalized patients or those visiting emergency departments; rapid diagnostic tests are generally not performed in outpatient clinics. However, despite these limitations, our study contributes preliminary insights that warrant further investigation using more comprehensive and representative datasets. Given the currently low level of awareness among clinicians regarding RSV infection, it is necessary to conduct research to assess their knowledge and awareness of the disease. In addition, a large-scale prospective study using highly sensitive PCR-based testing in patients presenting with respiratory or febrile symptoms is needed to evaluate the clinical characteristics and disease burden of RSV infection by age group and comorbidity status. Furthermore, studies assessing the duration of neutralizing antibody immunity and the rate of reinfection following RSV infection are essential for establishing future RSV vaccination strategies.
This study highlights that SARS-CoV-2 is more severe in patients aged 65 and older, particularly those with multiple underlying medical conditions, emphasizing the critical role of vaccination in these populations. Additionally, the potential underestimation of the RSV disease burden suggests a need for increased clinician awareness. Furthermore, developing standardized clinical diagnostic criteria for RSV infections, similar to those for influenza-like illnesses, could be beneficial for early diagnosis and treatment.
Supplementary Materials
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pathogens14060543/s1, Table S1: Risk of pneumonia development by each underlying disease in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Table S2: Risk assessment of ICU admission for each underlying disease in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Table S3: Risk assessment of mortality for each underlying disease in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Author Contributions
Conceptualization: Y.J.C. and J.Y.S.; Methodology and validation: Y.J.C. and J.Y.S.; Formal analysis: Y.J.C.; Data curation and investigation: Y.J.C., J.Y.S., S.-H.W., W.S.C., J.L., J.-S.L., Y.K.K., S.W.K., S.H.L., K.-H.P., H.W.J., J.G.Y., H.S., E.N., J.Y.N., H.J.C. and W.J.K.; Writing—original draft: Y.J.C. and J.Y.S.; Writing—review and editing: Y.J.C., J.Y.S., S.-H.W., W.S.C., J.L., J.-S.L., Y.K.K., S.W.K., S.H.L., K.-H.P., H.W.J., J.G.Y., H.S., E.N., J.Y.N., H.J.C. and W.J.K.; Funding acquisition: W.J.K. All authors have read and agreed to the published version of the manuscript.
Funding
This work was supported by a grant from the Korea University College of Medicine (Q2204881) underwritten by SK Bioscience Co. Ltd.
Institutional Review Board Statement
This study was approved by the Institutional Review Board of each participating hospital: Korea University Guro Hospital, 2022GR0360; Korea University Anam Hospital, 2022AN0449; Korea University Ansan Hospital, 2022AS0226; St. Vincent’s Hospital, VC22TIDI0150; Kangnam Sacred Heart Hospital, HKS, 2022-07-016; Inha University Hospital, 2022-07-036; Chungbuk National University Hospital, 2022-08-022; and Gil Medical Center, GAIRB2022-306. It was conducted in accordance with The Code of Ethics of the World Medica Association (Declaration of Helsinki).
Informed Consent Statement
The requirement for written informed consent was waived due to the retrospective nature of this study.
Data Availability Statement
The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.
Acknowledgments
This study used the database of the Hospital-based Influenza Morbidity and Mortality (HIMM) surveillance system. The authors express their sincere gratitude to all colleagues at the Vaccine Innovation Center-KU Medicine (VIC-K).
Conflicts of Interest
All authors confirm that they meet the ICMJE criteria for authorship and have no conflicts of interest to declare.
References
- Ippolito, G.; La Vecchia, A.; Umbrello, G.; Di Pietro, G.; Bono, P.; Scalia Catenacci, S.; Pinzani, R.; Tagliabue, C.; Bosis, S.; Agostoni, C.; et al. Disappearance of seasonal respiratory viruses in children under two years old during COVID-19 pandemic: A monocentric retrospective study in Milan, Italy. Front. Pediatr. 2021, 9, 721005. [Google Scholar] [CrossRef] [PubMed]
- Liu, P.; Xu, M.; Cao, L.; Su, L.; Lu, L.; Dong, N.; Jia, R.; Zhu, X.; Xu, J. Impact of COVID-19 pandemic on the prevalence of respiratory viruses in children with lower respiratory tract infections in China. Virol. J. 2021, 18, 159. [Google Scholar] [CrossRef] [PubMed]
- Yakovlev, A.S.; Belyaletdinova, I.K.; Mazankova, L.N.; Samitova, E.R.; Osmanov, I.M.; Gavelya, N.V.; Volok, V.P.; Kolpakova, E.S.; Shishova, A.A.; Dracheva, N.A.; et al. SARS-CoV-2 infection in children in Moscow in 2020: Clinical features and impact on circulation of other respiratory viruses: SARS-CoV-2 infection in children in Moscow in 2020. Int. J. Infect. Dis. 2022, 116, 331–338. [Google Scholar] [CrossRef] [PubMed]
- Ye, Q.; Wang, D. Epidemiological changes of common respiratory viruses in children during the COVID-19 pandemic. J. Med. Virol. 2022, 94, 1990–1997. [Google Scholar] [CrossRef]
- Zeng, Z.; Guan, W.; Liu, Y.; Lin, Z.; Liang, W.; Liang, J.; Chen, B.; Wu, T.; Wang, Y.; Yang, C.; et al. Different circulation pattern of multiple respiratory viruses in southern China during the COVID-19 pandemic. Front. Microbiol. 2021, 12, 801946. [Google Scholar] [CrossRef]
- Cha, J.; Seo, Y.; Kang, S.; Kim, I.; Gwack, J. Sentinel surveillance results for influenza and acute respiratory infections during the coronavirus disease 2019 pandemic. Public Health Wkly. Rep. 2023, 16, 597–612. Available online: https://www.phwr.org/submission/Journal/016/PHWR_016_20_FULL.pdf (accessed on 10 July 2024).
- Cavallazzi, R.; Ramirez, J.A. Influenza and viral pneumonia. Clin. Chest Med. 2018, 39, 703–721. [Google Scholar] [CrossRef]
- Ruiz, M.; Ewig, S.; Torres, A.; Arancibia, F.; Marco, F.; Mensa, J.; Sanchez, M.; Martinez, J.A. Severe community-acquired pneumonia: Risk factors and follow-up epidemiology. Am. J. Respir. Crit. Care Med. 1999, 160, 923–929. [Google Scholar] [CrossRef]
- Lynch, J.P. III. Hospital-acquired pneumonia: Risk factors, microbiology, and treatment. Chest 2001, 119, 373S–384S. [Google Scholar] [CrossRef]
- Vila-Corcoles, A.; Aguirre-Chavarria, C.; Ochoa-Gondar, O.; de Diego, C.; Rodriguez-Blanco, T.; Gomez, F.; Raga, X.; Barnes, L.; Magarolas, R.; Esteban, L. Influence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults. Infection 2015, 43, 699–706. [Google Scholar] [CrossRef]
- Choi, M.J.; Song, J.Y.; Noh, J.Y.; Yoon, J.G.; Lee, S.N.; Heo, J.Y.; Yoon, J.W.; Jo, Y.M.; Cheong, H.J.; Kim, W.J. Disease burden of hospitalized community-acquired pneumonia in South Korea: Analysis based on age and underlying medical conditions. Medicine 2017, 96, e8429. [Google Scholar] [CrossRef] [PubMed]
- Liang, C.; Begier, E.; Hagel, S.; Ankert, J.; Wang, L.; Schwarz, C.; Bayer, L.J.; von Eiff, C.; Liu, Q.; Southern, J.; et al. Estimated Incidence of respiratory syncytial virus (RSV)-related Hospitalizations for acute respiratory infections (ARIs), including community acquired pneumonia (CAP), in Adults in Germany. medRxiv 2024. medRxiv:06.09.24308507. [Google Scholar] [CrossRef]
- Sharp, A.; Minaji, M.; Panagiotopoulos, N.; Reeves, R.; Charlett, A.; Pebody, R. Estimating the burden of adult hospital admissions due to RSV and other respiratory pathogens in England. Influenza Other Respir. Viruses 2022, 16, 125–131. [Google Scholar] [CrossRef] [PubMed]
- Fleming, D.M.; Taylor, R.J.; Lustig, R.L.; Schuck-Paim, C.; Haguinet, F.; Webb, D.J.; Logie, J.; Matias, G.; Taylor, S. Modelling estimates of the burden of respiratory syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect. Dis. 2015, 15, 443. [Google Scholar] [CrossRef]
- Petrilli, C.M.; Jones, S.A.; Yang, J.; Rajagopalan, H.; O’Donnell, L.; Chernyak, Y.; Tobin, K.A.; Cerfolio, R.J.; Francois, F.; Horwitz, L.I. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study. BMJ 2020, 369, m1966. [Google Scholar] [CrossRef]
- Izcovich, A.; Ragusa, M.A.; Tortosa, F.; Lavena Marzio, M.A.; Agnoletti, C.; Bengolea, A.; Ceirano, A.; Espinosa, F.; Saavedra, E.; Sanguine, V.; et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS ONE 2020, 15, e0241955. [Google Scholar] [CrossRef]
- Martinón-Torres, F.; Gutierrez, C.; Cáceres, A.; Weber, K.; Torres, A. How does the burden of respiratory syncytial virus compare to influenza in Spanish adults? Influenza Other Respir. Viruses 2024, 18, e13341. [Google Scholar] [CrossRef]
- Walsh, E.E.; Peterson, D.R.; Falsey, A.R. Risk factors for severe respiratory syncytial virus infection in elderly persons. J. Infect. Dis. 2004, 189, 233–238. [Google Scholar] [CrossRef]
- Martínez, A.; Soldevila, N.; Romero-Tamarit, A.; Torner, N.; Godoy, P.; Rius, C.; Jané, M.; Domínguez, À.; Surveillance of Hospitalized Cases of Severe Influenza in Catalonia Working Group. Risk factors associated with severe outcomes in adult hospitalized patients according to influenza type and subtype. PLoS ONE 2019, 14, e0210353. [Google Scholar] [CrossRef]
- Mertz, D.; Kim, T.H.; Johnstone, J.; Lam, P.P.; Science, M.; Kuster, S.P.; Fadel, S.A.; Tran, D.; Fernandez, E.; Bhatnagar, N.; et al. Populations at risk for severe or complicated influenza illness: Systematic review and meta-analysis. BMJ 2013, 347, f5061. [Google Scholar] [CrossRef]
- Song, J.Y.; Lee, J.S.; Wie, S.H.; Kim, H.Y.; Lee, J.; Seo, Y.B.; Jeong, H.W.; Kim, S.W.; Lee, S.H.; Park, K.H.; et al. Prospective cohort study on the effectiveness of influenza and pneumococcal vaccines in preventing pneumonia development and hospitalization. Clin. Vaccine Immunol. 2015, 22, 229–234. [Google Scholar] [CrossRef]
- Tian, J.; Zhang, L.; Wang, X.; Huang, G.; Li, Z.; Gong, L.; Liu, D. Clinical features and survival analysis of adult patients with severe lower respiratory tract infection positive for respiratory syncytial virus. BMC Pulm. Med. 2025, 25, 184. [Google Scholar] [CrossRef] [PubMed]
- Perčinić, A.; Vuletić, T.; Lizzul, N.; Vukić Dugac, A.; Gverić Grginić, A.; Tabain, I.; Jurić, D.; Budimir, A. Epidemiological and Clinical Characteristics of Adult RSV Infections: A Retrospective Analysis at University Hospital Center Zagreb (2022–2024). Pathogens 2025, 14, 284. [Google Scholar] [CrossRef] [PubMed]
- Lee, N.; Lui, G.C.; Wong, K.T.; Li, T.C.; Tse, E.C.; Chan, J.Y.; Yu, J.; Wong, S.S.; Choi, K.W.; Wong, R.Y.; et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin. Infect. Dis. 2013, 57, 1069–1077. [Google Scholar] [CrossRef]
- Jung, Y.H. Analysis of complex chronic diseases in the elderly: Focusing on outpatient utilization. Health Welf. Issue Focus. 2013, 196, 1–8. [Google Scholar]
- Jeong, K.H.; Oh, Y.H.; Kang, E.N.; Kim, K.R.; Lee, Y.K.; Oh, M.A.; Hwang, N.H.; Kim, S.J.; Lee, S.H.; Lee, S.G.; et al. Survey of the Elderly, Ministry of Health and Welfare; Korea Institute for Health and Social Affairs: Republic of Korea, 2017; Volume 53, pp. 310–313. Available online: https://www.mohw.go.kr/board.es?mid=a10411010200&bid=0019&act=view&list_no=344953 (accessed on 10 July 2024).
- Presti, S.; Manti, S.; Gambilonghi, F.; Parisi, G.F.; Papale, M.; Leonardi, S. Comparative analysis of pediatric hospitalizations during two consecutive influenza and respiratory virus seasons post-pandemic. Viruses 2023, 15, 1825. [Google Scholar] [CrossRef]
- Presti, S.; Manti, S.; Gammeri, C.; Parisi, G.F.; Papale, M.; Leonardi, S. Leonardi, Epidemiological shifts in bronchiolitis patterns and impact of COVID-19: A two-season comparative study. Pediatr. Pulmonol. 2024, 59, 129–1304. [Google Scholar] [CrossRef]
Table 1.
Baseline characteristics of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus (INFV), or respiratory syncytial virus (RSV) infection.
Table 1.
Baseline characteristics of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus (INFV), or respiratory syncytial virus (RSV) infection.
| Variable | SARS-CoV-2 (N = 1850) | INFV (N = 98) | RSV (N = 63) | p-Value |
|---|---|---|---|---|
| Age | 70.2 ± 15.8 | 67.3 ± 17.9 | 68.9 ± 14.1 | 0.175 |
| 19–49 years | 201 (10.9) | 17 (17.3) | 7 (11.1) | |
| 50–64 years | 365 (19.7) | 17 (17.3) | 12(19.0) | |
| ≥65 years | 1284 (69.4) | 64 (65.3) | 44 (69.8) | |
| Sex, male | 1066 (57.6) | 49 (50.0) | 38 (60.3) | 0.294 |
| Risk group | 0.377 | |||
| Low risk | 368 (19.9) | 22 (22.4) | 18 (28.6) | |
| Moderate risk | 956 (51.7) | 52 (53.1) | 38 (60.3) | |
| High risk | 525 (28.4) | 24 (24.5) | 7 (11.1) | |
| Underlying diseases | ||||
| Hypertension | 1107 (59.8) | 58 (59.2) | 25 (39.7) | 0.105 |
| Diabetes mellitus | 758 (40.1) | 36 (36.7) | 22 (34.9) | 0.985 |
| Cardiovascular diseases | 396 (21.4) | 20 (20.4) | 8 (12.7) | 0.575 |
| Cerebrovascular diseases | 338 (18.3) | 28 (28.6) | 9 (14.3) | 0.116 |
| Neuromuscular diseases | 123 (6.6) | 10 (10.2) | 10 (15.9) | 0.051 |
| COPD | 78 (4.2) | 6 (6.1) | 6 (9.5) | 0.314 |
| Asthma | 63 (3.4) | 7 (7.1) | 2 (3.2) | 0.422 |
| Other chronic lung diseases | 66 (3.6) | 8 (8.2) | 8 (12.7) | 0.002 * |
| History of tuberculosis | 75 (4.1) | 2 (2.0) | 4 (6.3) | 0.741 |
| Chronic renal diseases | 261 (14.1) | 9 (9.2) | 9 (14.3) | 0.737 |
| Chronic liver diseases | 87 (4.7) | 2 (2.0) | 3 (4.8) | 0.808 |
| Solid cancer | 395 (21.3) | 13 (13.3) | 13 (20.6) | 0.437 |
| Hematology malignancy | 78 (4.2) | 4 (4.1) | 6 (9.5) | 0.637 |
| Bone marrow transplant | 6 (0.3) | 1 (1.0) | 3 (4.8) | <0.001 * |
| Solid organ transplant | 12 (0.6) | 1 (1.0) | 0 (0.0) | 0.992 |
| Autoimmune diseases | 36 (1.9) | 5 (5.1) | 0 (0.0) | 0.619 |
| Immunosuppressants user | 125 (6.8) | 9 (9.2) | 5 (7.9) | 0.903 |
| HIV | 5 (0.3) | 0 (0.0) | 0 (0.0) | 0.971 |
| Symptom | ||||
| None | 272 (14.7) | 1 (1.0) | 3 (4.8) | <0.001 * |
| Fever | 1030 (55.6) | 76 (77.6) | 37 (58.7) | <0.001 * |
| Cough | 581 (31.4) | 51 (52.0) | 29 (46.0) | <0.001 * |
| Sputum | 523 (28.3) | 45 (45.9) | 34 (54.0) | <0.001 * |
| Sore throat | 176 (9.5) | 11 (11.2) | 2 (3.2) | 0.484 |
| Rhinorrhea | 116 (6.3) | 12 (12.2) | 6 (9.5) | 0.174 |
| Dyspnea | 516 (27.9) | 35 (35.7) | 40 (63.5) | <0.001 * |
| Admission route | 0.192 | |||
| OPD | 342 (18.5) | 15 (15.3) | 16 (25.4) | |
| ER | 1439 (77.7) | 77 (78.6) | 47 (74.6) | |
| Nosocomial infection | 69 (3.7) | 6 (6.1) | 0 (0.0) | |
| Laboratory findings | ||||
| Total WBC counts | 8.55 ± 7.6 | 8.82 ± 8.1 | 9.85 ± 5.5 | 0.390 |
| AST | 48.4 ± 92.5 | 48.3 ± 71.2 | 36.9 ± 25.3 | 0.618 |
| ALT | 33.0 ± 58.4 | 30.8 ± 38.7 | 31.1 ± 31.3 | 0.910 |
| LDH | 329.6 ± 291.5 | 327.9 ± 192.5 | 366.1 ± 196.6 | 0.722 |
| CPK | 237.1 ± 657.4 | 248.5 ± 472.0 | 149.9 ± 197.9 | 0.663 |
| D-dimer | 3.1 ± 5.9 | 1.8 ± 2.0 | 2.3 ± 2.2 | 0.245 |
| Pro-BNP | 2659.9 ± 6779.1 | 3105.7 ± 7023.7 | 2638.6 ± 4975.8 | 0.909 |
| ESR | 41.7 ± 31.2 | 39.13 ± 34.3 | 58.30 ± 35.4 | 0.006 * |
| CRP | 50.7 ± 71.5 | 95.45 ± 92.2 | 108.06 ± 103.0 | <0.001 * |
| Radiologic findings (CXR) | ||||
| With pneumonia | 636 (34.4) | 42 (42.9) | 42 (66.7) | <0.001 * |
| Vaccination | ||||
| Influenza vaccination | 818 (44.2) | 46 (46.9) | 38 (60.3) | 0.157 |
| COVID-19 vaccination | 1537 (83.0) | 87 (88.8) | 59 (93.7) | 0.138 |
| Pneumococcal vaccination | 1044 (56.4) | 55 (56.1) | 46 (73.0) | 0.315 |
Data are presented as the mean ± standard deviation or No (%). COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; OPD, outpatient department; ER, emergency room; WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CPK, creatine phosphokinase; pro-BNP, pro-brain natriuretic peptide; ESR, erythrocyte sedimentation rate; CRP, c-reactive protein; CXR, chest x-ray; COVID-19, coronavirus disease 2019. * p < 0.05.
Table 2.
Comparison of clinical outcomes among patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus (INFV), or respiratory syncytial virus (RSV) infection.
Table 2.
Comparison of clinical outcomes among patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus (INFV), or respiratory syncytial virus (RSV) infection.
| Outcomes | SARS-CoV-2 (N = 1850) | INFV (N = 98) | RSV (N = 63) | p-Value |
|---|---|---|---|---|
| Cases with pneumonia | 39 (39.8) | 459 (24.8) | 44 (69.8) | <0.001 * |
| ICU admission | 19 (19.4) | 406 (21.9) | 16 (25.0) | 0.925 |
| ARDS | 4 (4.1) | 49 (2.6) | 2 (3.1) | 0.682 |
| Mortality | 7 (7.1) | 189 (10.2) | 7 (10.9) | 0.594 |
| Days of hospitalization | 19.2 ± 26.7 | 14.3 ± 17.6 | 16.5 ± 11.9 | 0.141 |
Data are presented as the mean ± standard deviation or No (%). ICU, intensive care unit; ARDS, acute respiratory distress syndrome. * p < 0.05.
Table 3.
Risk of pneumonia development by underlying medical conditions among patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus (INFV), or respiratory syncytial virus (RSV) infection.
Table 3.
Risk of pneumonia development by underlying medical conditions among patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus (INFV), or respiratory syncytial virus (RSV) infection.
| Underlying Medical Conditions | SARS-CoV-2 (N = 1850) | INFV (N = 98) | RSV (N = 63) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No (%) | OR (95% CI) | p-Value | No (%) | OR (95% CI) | p-Value | No (%) | OR (95% CI) | p-Value | |
| Low risk | 65/368 (17.7) | reference | 5/22 (22.7) | reference | 5/7 (71.4) | reference | |||
| Moderate risk | 269/956 (28.1) | 1.47 (1.07–2.01) | 0.017 | 25/52 (48.1) | 2.47 (0.66–9.20) | 0.178 | 27/38 (71.1) | 1.08 (0.17–6.90) | 0.938 |
| 1 chronic medical condition | 121/450 (26.9) | 1.46 (1.03–2.08) | 0.034 | 10/21 (47.6) | 2.55 (0.60–10.85) | 0.205 | 16/21 (76.2) | 1.40 (0.19–10.23) | 0.740 |
| 2 chronic medical conditions | 93/319 (29.2) | 1.54 (1.06–2.23) | 0.024 | 8/17 (47.1) | 2.49 (0.51–12.17) | 0.261 | 7/10 (70.0) | 1.02 (0.11–9.20) | 0.990 |
| ≥3 chronic medical conditions | 55/187 (29.4) | 1.37 (0.89–2.10) | 0.154 | 7/14 (50.0) | 2.32 (0.47–11.58) | 0.304 | 4/7 (57.1) | 0.56 (0.06–5.58) | 0.618 |
| High risk | 124/525 (23.6) | 1.37 (0.90–1.93) | 0.074 | 9/24 (37.5) | 1.83 (0.47–7.22) | 0.387 | 12/18 (66.7) | 0.81 (0.11–5.83) | 0.838 |
Results with p < 0.05 are bolded. OR, odds ratio; CI, confidence interval.
Table 4.
Risk of admission to intensive care unit by underlying medical conditions among patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus (INFV), or respiratory syncytial virus (RSV) infection.
Table 4.
Risk of admission to intensive care unit by underlying medical conditions among patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus (INFV), or respiratory syncytial virus (RSV) infection.
| Underlying Medical Conditions | SARS-CoV-2 (N = 1850) | INFV (N = 98) | RSV (N = 63) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No, (%) | OR (95% CI) | p-Value | No, (%) | OR (95% CI) | p-Value | No, (%) | OR (95% CI) | p-Value | |
| Low risk | 74/368 (20.1) | reference | 3/22 (13.6) | reference | 1/7 (14.3) | reference | |||
| Moderate risk | 250/706 (26.2) | 1.31 (0.97–1.77) | 0.810 | 8/52 (15.4) | 0.46 (0.09–2.42) | 0.362 | 10/38 (26.3) | 3.10 (0.28–34.68) | 0.359 |
| 1 chronic medical condition | 98/450 (21.8) | 1.07 (0.76–1.51) | 0.713 | 3/21 (14.3) | 0.46 (0.07–10.09) | 0.423 | 2/21 (9.5) | 1.00 (0.24–38.00) | 0.998 |
| 2 chronic medical conditions | 86/319 (27.0) | 1.38 (0.96–1.51) | 0.086 | 2/17 (11.8) | 0.30 (0.04–2.52) | 0.269 | 3/10 (30.0) | 4.55 (0.28–73.58) | 0.286 |
| ≥3 chronic medical conditions | 66/187 (35.3) | 1.38 (0.96–1.99) | 0.001 | 3/14 (21.4) | 0.67 (0.10–4.63) | 0.686 | 5/7 (71.4) | 28.23 (1.38–576.83) | 0.030 |
| High risk | 82/443 (15.6) | 0.71 (0.50–1.02) | 0.060 | 8/24 (33.3) | 2.10 (0.44–10.09) | 0.355 | 5/18 (27.8) | 2.64 (0.22–32.05) | 0.447 |
Results with p < 0.05 are bolded. OR, odds ratio; CI, confidence interval.
Table 5.
Risk of in-hospital mortality by underlying medical conditions among patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus (INFV), or respiratory syncytial virus (RSV) infection.
Table 5.
Risk of in-hospital mortality by underlying medical conditions among patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus (INFV), or respiratory syncytial virus (RSV) infection.
| Underlying Medical Conditions | SARS-CoV-2 (N = 1850) | INFV | RSV | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No, (%) | OR (95% CI) | p-Value | No, (%) | OR (95% CI) | p-Value | No, (%) | OR (95% CI) | p-Value | |
| Low risk | 33/368 (9.0) | reference | 1/22 (4.5) | reference | 1/7 (14.3) | reference | |||
| Moderate risk | 86/956 (9.0) | 0.73 (0.97–2.42) | 0.155 | 1/52 (1.9) | 0.32 (0.01–7.12) | 0.470 | 2/38 (5.3) | 0.50 (0.03–7.66) | 0.616 |
| 1 chronic medical condition | 32/450 (7.1) | 0.60 (0.38–1.02) | 0.058 | 0/21 (0.0) | N/A | N/A | 0/21 (0.0) | N/A | N/A |
| 2 chronic medical conditions | 29/319 (9.1) | 0.74 (0.43–1.27) | 0.280 | 0/17 (0.0) | N/A | N/A | 0/10 (0.0) | N/A | N/A |
| ≥3 chronic medical conditions | 25/187 (13.4) | 0.98 (0.55–1.74) | 0.940 | 1/14 (7.1) | 1.11 (0.05–25.64) | 0.950 | 2/7 (28.6) | 4.19 (0.20–87.26) | 0.355 |
| High risk | 70/525 (13.3) | 1.53 (0.97–2.42) | 0.065 | 5/24 (20.8) | 4.62 (0.44–48.62) | 0.203 | 4/18 (22.2) | 2.16 (0.16–28.32) | 0.558 |
OR, odds ratio; CI, confidence interval; N/A, non-applicable.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Choi, Y.J.; Song, J.Y.; Wie, S.-H.; Choi, W.S.; Lee, J.; Lee, J.-S.; Kim, Y.K.; Kim, S.W.; Lee, S.H.; Park, K.-H.; et al. Severity of Respiratory Viral Diseases and the Impacts of Underlying Medical Conditions During the Omicron Subvariant Dominant Epidemics—A Comparative Study of SARS-CoV-2, Influenza Virus and Respiratory Syncytial Virus. Pathogens 2025, 14, 543. https://doi.org/10.3390/pathogens14060543
AMA Style
Choi YJ, Song JY, Wie S-H, Choi WS, Lee J, Lee J-S, Kim YK, Kim SW, Lee SH, Park K-H, et al. Severity of Respiratory Viral Diseases and the Impacts of Underlying Medical Conditions During the Omicron Subvariant Dominant Epidemics—A Comparative Study of SARS-CoV-2, Influenza Virus and Respiratory Syncytial Virus. Pathogens. 2025; 14(6):543. https://doi.org/10.3390/pathogens14060543
Chicago/Turabian StyleChoi, Yu Jung, Joon Young Song, Seong-Heon Wie, Won Suk Choi, Jacob Lee, Jin-Soo Lee, Young Keun Kim, Shin Woo Kim, Sun Hee Lee, Kyung-Hwa Park, and et al. 2025. "Severity of Respiratory Viral Diseases and the Impacts of Underlying Medical Conditions During the Omicron Subvariant Dominant Epidemics—A Comparative Study of SARS-CoV-2, Influenza Virus and Respiratory Syncytial Virus" Pathogens 14, no. 6: 543. https://doi.org/10.3390/pathogens14060543
APA StyleChoi, Y. J., Song, J. Y., Wie, S.-H., Choi, W. S., Lee, J., Lee, J.-S., Kim, Y. K., Kim, S. W., Lee, S. H., Park, K.-H., Jeong, H. W., Yoon, J. G., Seong, H., Nham, E., Noh, J. Y., Cheong, H. J., & Kim, W. J. (2025). Severity of Respiratory Viral Diseases and the Impacts of Underlying Medical Conditions During the Omicron Subvariant Dominant Epidemics—A Comparative Study of SARS-CoV-2, Influenza Virus and Respiratory Syncytial Virus. Pathogens, 14(6), 543. https://doi.org/10.3390/pathogens14060543
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
